MGC has completed all architectural plans for its GMP-certified medicinal cannabis production and cultivation facility in Malta, following the release by the Maltese Medical Authority of guidelines on the manufacturing and cultivation of cannabis for medicinal and research purposes. Formal contracts with Maltese government authorities for a long-term lease are expected to be signed in the coming weeks, following by the commencement of construction. The lease negotiations are the next step in the process that began when MGC signed a binding letter of intent with the Maltese government in April 2018 for the establishment of a 4,000m2 medicinal cannabis facility.
The company expects to be able to leverage the key expertise that it developed as it obtained EU GMP certification for its Slovenian medical cannabis manufacturing and production facility in order to expedite development in Malta.
"Thanks to its warm climate, the Maltese facility is expected to produce high-yielding cannabis crops at a relatively low cost. Once operational, it will become the hub of the company’s seed-to-pharma operations focused on supplying key markets in Europe, the UK and internationally", the team with the company concludes.
For more information:
MGC Pharma
info@mgcpharma.com.au
mgcpharma.com.au